$ATOS

Atossa Therapeutics (ATOS) has entered into a CVR Agreement, granting shareholders 25% of net proceeds from the sale of its first qualifying FDA priority review voucher, capped at $50M. The CVRs are stapled to shares and will be issued on October 19, 2026. The company aims to develop innovative medicines in oncology and other areas of significant unmet need, with (Z)-endoxifen as its lead product candidate.

Ascendiant Capital kept a Buy rating on Atossa Therapeutics with a $25 price target, suggesting a 1182.1% upside from the Sep 30 close. The company's lead product, oral (Z)-endoxifen, is in Phase 2 trials for breast cancer, with a potential market of $1 billion.

ATOSSA THERAPEUTICS, INC. (ATOS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders

Atossa Therapeutics released an updated corporate presentation, highlighting progress in its (Z)-Endoxifen programs for oncology, MAS, and DMD. The company reported $26.1M in cash and no debt as of June 30, 2026, with funding expected to last into 2027. Key regulatory milestones and clinical updates were also provided, including Rare Pediatric Disease designations and planned Phase 2 trials for 2027.

According to an analysis of Atossa Therapeutics (NASDAQ:ATOS), the company had about $26m cash and no debt as of June 2026. Its last-year cash burn was about $36m, implying a cash runway of roughly 9 months. The article also says cash burn rose 43% year over year and cash burn exceeded market cap.

Atossa Therapeutics (Nasdaq: ATOS) reported second-quarter 2026 results for the quarter ended June 30, 2026 and provided a corporate update. The company highlighted scientific updates for (Z)-endoxifen in rare pediatric diseases and ER+ breast cancer, including EVANGELINE Phase 2 progress. Atossa also completed a registered direct offering raising $4.5 million upfront, with potential gross proceeds up to $16.5 million.

ATOSSA THERAPEUTICS, INC. (ATOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, WASHINGTON, August 7, 2026 — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncol

According to Stat News and an SEC filing by California-based Immix Biopharma, Richard Graydon, an alias for fugitive Ronald Fischer, was arrested July 16 in New York after 20 years on the run. Immix said it terminated Graydon on Friday for reasons unrelated to company activities and expects no material business impact. Atossa previously hired him as interim CMO.

ATOSSA THERAPEUTICS, INC. (ATOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 atos-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 10, 2026, between Atossa Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on

Atossa Genetics Inc. (NASDAQ:ATOS) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $6.33. The biotechnology company, focused on breast cancer therapeutics, currently trades around $0.65. Institutional ownership stands at approximately 12.74%, with notable recent increases from firms like Bank of America and Qube Research & Technologies.